Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

EXCLUSION CRITERIA

  • Known contraindication to co-amoxiclav
  • Child given antibiotics within the last 72 hours
  • Child requires immediate antibiotics or hospital admission (clinician’s judgement)
  • Any reason to prevent healthcare professional from obtaining high nasal swab
  • Child with known cystic fibrosis
  • Child previously entered into the ARCHIE study
  • Child has been involved in another medicinal trial within the last 90 days

Contraindications to co-amoxiclav

  • Known hypersensitivity to beta-lactam antibiotics or clavulanic acid
  • History of jaundice or hepatic impairment due to co-amoxiclav
  • Severe liver disease§§ (as defined in 'at risk' categories)
  • Known or suspected infectious mononucleosis
  • Known lymphocytic leukaemia
  • Known phenylketonuria
  • eGFR less than 30 ml/min/1.73m2  (based on most recent measurement within the last 12 months)
  • Currently taking any medications known to interact with co-amoxiclav (e.g. probenecid, sulfasalazine, methotrexate, digoxin, oral anticoagulants) or increase the risk of adverse reactions to co-amoxiclav (allopurinol)